Loading
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Previous close
$81.92
+$0.72 · +0.89%
Regular session · ET · Market data may be delayed.
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Day range
Current $81.92
52-week range
Current $81.92
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Buy
Favorable setup — positive multi-factor alignment
Valuation
78
Undervalued
Sentiment
65
Bullish
Risk
20
Low Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Day range
Current $81.92
52-week range
Current $81.92
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.39B USD | 1.25B USD | 1.15B USD | 1.02B USD | 1.04B USD |
| Cost of goods sold | 448.2M USD | 382.56M USD | 382.3M USD | 314.58M USD | 329.37M USD |
| Gross profit | 939.9M USD | 870.87M USD | 771.25M USD | 707.23M USD | 705.99M USD |
| Research and development | 185.8M USD | 182.51M USD | 193.82M USD | 155.81M USD | 183.41M USD |
| Selling, general, and administrative | 548.8M USD | 526.27M USD | 518.13M USD | 469.24M USD | 471.9M USD |
| Operating expenses | 740.5M USD | 741.82M USD | 839.75M USD | 783.98M USD | 706.78M USD |
| Interest income | 18.98M USD | 30.08M USD | 22.01M USD | 4.7M USD | 435K USD |
| Interest expense | 49.29M USD | 63.07M USD | 58.85M USD | 48.25M USD | 50.15M USD |
| Depreciation and amortization | 42M USD | 51.14M USD | 60.86M USD | 57.8M USD | 67.99M USD |
| Operating income | 199.4M USD | 129.05M USD | −68.5M USD | −76.75M USD | −784K USD |
| Net income | −242.5M USD | 63.23M USD | 17.55M USD | −86.25M USD | −135.82M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$88.50
8.03% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Mid-Cap ETFIJH154.73M0.12%124.57B USD0.05%$75.85+0.13%
Avantis U.S. Small Cap Value ETFAVUV130.87M0.41%31.49B USD0.25%$126.93+0.52%
iShares Russell 2000 ETFIWM114.46M0.14%79.88B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF50.64M0.05%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Value ETFIWN33.2M0.23%14.47B USD0.24%$224.62+0.40%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY32.76M0.12%26.51B USD0.23%$691.52+0.13%
Invesco S&P MidCap Quality ETFXMHQ30.61M0.55%5.62B USD0.30%$118.08-0.25%
iShares S&P Mid-Cap 400 Growth ETFIJK26.15M0.23%10.64B USD0.16%$113.45+0.06%iShares Core S&P Mid-Cap ETFIJHAvantis U.S. Small Cap Value ETFAVUViShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNState Street SPDR S&P MIDCAP 400 ETF TrustMDYInvesco S&P MidCap Quality ETFXMHQiShares S&P Mid-Cap 400 Growth ETFIJKAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
